Alkermes excitedly announced extremely positive study data from a Phase 3 trial of Aripiprazole. This randomized, placebo-controlled and double-blind study gleaned better than expected results, leading pharmaceutical executives at Alkermes to set a plan in motion for an NDA by the third quarter of 2014. As a long acting and injectable antipsychotic treatment Aripiprazole Lauroxil[…]
Positive Study Results for Aripiprazole Will Lead to NDA
Antipsychotic, NDA, OTC and Compounding Product Tags: Bipolar DisorderSchizophrenia Apr 18, 2014
Metronidazole 1.3% Gel Approved by the FDA for BV
Antibacterial, FDA Approved 2014, OTC and Compounding Product Tags: antibiotic Apr 02, 2014
On March 25, 2014 Actavis and Valeant Pharmaceuticals announced the FDA approval of Metronidazole 1.3% gel for the antibiotic treatment of Bacterial Vaginosis. Bacterial Vaginosis, or BV, is an extremely common vaginal infection which commonly affects women between the ages of 15 and 44. An imbalance of normal bacteria in the vagina is the leading[…]
Bortezomib for Multiple Myeloma Touted as First Line Treatment in the U.K.
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, OTC and Compounding Product Tags: multiple myeloma Mar 31, 2014
The National Institute for Health and Care Excellence {NICE} in the U.K. approved Bortezomib for multiple myeloma treatment on March 21, 2014. This serious, and often fatal blood cancer affects roughly 4500 patients in the U.K. each year. Multiple myeloma is projected to afflict about 24,000 new patients in the United States in 2014, with[…]
Raloxifene Treatment for Breast Cancer and Liver Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, OTC and Compounding Product, TEVA API Tags: breast cancer Mar 19, 2014
Positive Study Results As a common medication prescribed for post-menopausal women to treat and prevent osteoporosis, Raloxifene has now been recognized as a potential viable treatment for both breast and liver cancer. A recently released study, conducted at Oregon State University, demonstrated powerful data touting the use of Raloxifene to treat triple-negative breast cancer (TNBC)[…]
Unique Formulation of Indomethacin Gains FDA Approval
Analgesic, Anti-Inflammatory, FDA Approved 2014, OTC and Compounding Product Tags: NSAID Mar 18, 2014
The recent approval of two low dosage strengths of Indomethacin have been a boon for Iroko Pharmaceuticals. The FDA approved their twenty and forty milligram doses of the popular nonsteroidal anti-inflammatory drug under the brand name Tivorbex. As easy to swallow capsules, the approval of the lower dose Indomethacin will likely lead to fewer adverse[…]
2014 Study Reveals Rosuvastatin Calcium Most Effectual Post Heart Attack
OTC and Compounding Product, Patent Expiration 2020 Mar 04, 2014
Rosuvastatin Calcium, known as the brand name Crestor, has a patent expiration of August 4, 2020. Recent study data revealed that patients who received the high potency statin Rosuvastatin after a heart attack had a high survival rate. This study from the Cardiovascular division at the University of Dundee Medical School compared Ezetimibe with higher[…]
Desloratadine is Still Effectual and Tolerable for Allergy Sufferers
OTC and Compounding Product, TEVA API Tags: asthma Feb 07, 2014
Known as the brand name Clarinex, as well as Clarinex D 12 Hour, Desloratadine is a steadfast and tolerable treatment for allergies. Desloratadine offers anti-inflammatory benefits, as it is a selective H(1)-receptor antagonist. Known as a safe and effective antihistamine for both adults and children, it comes as no surprise that IMS Health released positive[…]
Desonide Continues to Thrive as a Treatment for Atopic Dermatitis
OTC and Compounding Product, Patent Expiration 2019 Feb 03, 2014
On June 4, 2013 Aqua Pharmaceuticals announced its acquisition of the brand name foam of Desonide, coined Verdeso, from Stiefel Pharmaceuticals. This announcement was extremely positive for Aqua Pharmaceuticals, as they already hold a thriving lineup of dermatologic products, such as Fluoroplex and Cordran. The addition of Verdeso, a foam formulation of Desonide, has filled[…]
Difluprednate Stands the Test of Time
Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2019 Dec 23, 2013
The first topical steroid, Difluprednate, known as the brand name Durezol, continues to prove itself year after year. As a difluorinated derivative of prednisolone, Difluprednate has been indicated to treat both eye pain and inflammation after surgery, as well as anterior uveitis. A recent clinical trial published on June 18, 2013 indicated success for participants[…]
Fluticasone Propionate Receives NDA but Remains in Short Supply
Anti-Asthma / COPD, Drug Research & Development API, NDA, OTC and Compounding Product Tags: asthma Nov 18, 2013
Fluticasone Propionate, which is currently short in supply, received a New Drug Application, or NDA at on July 31, 2013. Drug maker Perrigo announced the new drug application for fluticasone propionate lotion, 0.05%. This form of fluticasone propionate lotion is the generic equivalent to Cutivate Lotion, 0.05%. The use of the effectual and tolerable corticosteroid[…]
